Catabasis Pharmaceuticals Inc. shares information regarding new findings with edasalonexent. Through their initial lab results they have found suggestions that the heart rate significantly decreased from baseline in boys receiving edasalonexent to approximately the average rate for unaffected boys. Catabasis supports Rare Disease Day each year on the last day of February to raise awareness for those affected by rare diseases across the globe. The Catabasis team is proud of this tradition and to be a part of the Duchenne community.
To read the full newsletter you can find it here. For more information on Rare Disease Day, and to find an event near you, visit rarediseaseday.org